Zoledronic Acid 4mg/5ml Concentrate For Solution For Infusion
Claris Injectables Limited
Barcode Information:
|
Artwork Code : 1400005650 |
Artwork Req. No: 15121 |
|
Quality of Paper/Board : Super Sun Shine |
Size of Artwork (In mm) : 400x175 |
|
Quality of Gum : |
GSM of Paper/Board : 60 GSM |
Colour Code : BLACK Pantone Pantone Pantone Pantone Pantone Pantone Pantone
|
Barcode Scan Report: | |
|
Packing: 5ml Tubular Vial |
Plant Location : Injectable |
|
Country: United Kingdom |
Language : English |
|
Ref. Code Creation/Blockage Note: |
Artwork Control Key No.: |
“Controlled Copy” Holder (1) (2) (3) (4) (5)
Package leaflet: Information for the user
Zoledronic Acid 4mg/5ml concentrate for solution for infusion
Zoledronic acid
The name of your medicine is Zoledronic acid 4mg/5ml concentrate for solution for infusion, which will be referred to as Zoledronic acid throughout this leaflet.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist or nurse.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What Zoledronic acid is and what it is used for
2. What you need to know before you are given Zoledronic acid
3. How you will be given Zoledronic acid
4. Possible side effects
5. How to store Zoledronic acid
6. Contents of the pack and other information
1. What Zoledronic acid is and what it is used for
The active substance is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:
To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).
To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).
2. What you need to know before you are given Zoledronic acid
Your doctor will carry out blood tests before you start treatment
with Zoledronic acid and will check your response to treatment at
regular intervals.
Zoledronic acid should not be used
- if you are breast-feeding.
- if you are allergic to Zoledronic acid, another bisphosphonate (the group of substances to which Zoledronic acid belongs), or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Before you are given Zoledronic acid, tell your doctor:
- if you have or have had a kidney problem.
- if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. Your doctor may recommend a dental examination before you start treatment with Zoledronic acid.
- if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Zoledronic acid and inform your doctor about your dental treatment.
While being treated with Zoledronic acid, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw.
Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.
Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with Zoledronic acid. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening. If any of these apply to you, tell your doctor straight away. If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of zoledronic acid. You will be given adequate calcium and vitamin D supplements.
Patients aged 65 years and over
Zoledronic acid can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.
Children and adolescents
Zoledronic acid is not recommended for use in adolescents and children below the age of 18 years.
Other medicines and Zoledronic acid
Tell your doctor if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:
X...........................................................................................................
The following information is intended for healthcare professionals only:
How to prepare and administer Zoledronic acid
- To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic acid (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. If a lower dose of Zoledronic acid is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution.
- Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.
- Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.
- Aclasta (a medicine that also contains Zoledronic acid and is used to treat osteoporosis and other non-cancer diseases of the bone), or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic acid are unknown.
- Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zoledronic acid has been associated with reports of osteonecrosis of the jaw (ONJ).
Pregnancy and breast-feeding
You should not be given Zoledronic acid if you are pregnant. Tell your doctor if you are or think that you may be pregnant.
You must not be given Zoledronic acid if you are breast-feeding.
Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.
Driving and using machines
There have been very rare cases of drowsiness and sleepiness with the use of Zoledronic acid. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.
This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially 'sodium- free'.
3. How you will be given Zoledronic acid
- Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
- Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.
- Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.
How much Zoledronic acid is given
- The usual single dose given is 4 mg.
- If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.
How often Zoledronic acid is given
- If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zoledronic acid every three to four weeks.
- If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zoledronic acid .
How Zoledronic acid is given
- Zoledronic acid is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day
If you take more than Zoledronic acid than you should
If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.
Side effects are classified according to their frequency into the following categories:
|
very common: |
may affect more than 1 in 10 people |
|
common: |
may affect up to 1 in 10 people |
|
uncommon: |
may affect up to 1 in 100 people |
|
rare: |
may affect up to 1 in 1,000 people |
|
very rare: |
may affect up to 1 in 10,000 people |
|
unknown: |
frequency cannot be estimated from the available data |
Tell your doctor about any of the following serious side effects straight away:
Common:
Do not mix Zoledronic acid with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution.
Instructions for preparing reduced doses of Zoledronic acid : Withdraw the appropriate volume of the liquid concentrate, as follows:
- 4.4 ml for 3.5 mg dose
- 4.1 ml for 3.3 mg dose
- 3.8 ml for 3.0 mg dose
- For single use only. Any unused solution should be discarded. Only clear solution free from particles and discolouration should be used. Aseptic techniques must be followed during the preparation of the infusion.
Claris Injectables Limited
|
Artwork Code : 1400005650 |
Artwork Req. No: 15121 |
|
Quality of Paper/Board : Super Sun Shine |
Size of Artwork (In mm) : 400x175 |
|
Quality of Gum : |
GSM of Paper/Board : 60 GSM |
Colour Code : BLACK Pantone Pantone Pantone Pantone Pantone Pantone Pantone
Barcode Information:
|
Barcode Scan Report: | |
|
Packing: 5ml Tubular Vial |
Plant Location : Injectable |
|
Country: United Kingdom |
Language : English |
|
Ref. Code Creation/Blockage Note: |
Artwork Control Key No.: |
“Controlled Copy” Holder (1) (2) (3) (4) (5)
- Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).
- Low level of calcium in the blood.
Uncommon:
- Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zoledronic Acid or after stopping treatment.
- Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether Zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic acid.
- Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
Rare:
- As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).
- A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).
Very rare:
- As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Tell your doctor about any of the following side effects as soon as possible:
Very common:
- Low level of phosphate in the blood.
Common:
- Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).
- Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.
- Conjunctivitis.
- Low level of red blood cells (anaemia).
Uncommon:
- Hypersensitivity reactions.
- Low blood pressure.
- Chest pain.
- Skin reactions (redness and swelling) at the infusion site, rash, itching.
- High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbance, trembling, tingling or numbness of the hands or feet, diarrhea, constipation, abdominal pain, dry mouth.
- Low counts of white blood cells and blood platelets.
- Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures.
- Weight increase
- Increased sweating
- Sleepiness.
- Blurred vision, tearing of the eye, eye sensitivity to light.
- Sudden coldness with fainting, limpness or collapse.
- Difficulty in breathing with wheezing or coughing.
- Urticaria.
Rare:
- Slow heart beat.
- Confusion.
- Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.
- Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs).
- Flu-like symptoms including arthritis and joint swelling.
- Painful redness and/or swelling of the eye.
Very rare:
- Fainting due to low blood pressure.
- Severe bone, joint and/or muscle pain, occasionally incapacitating.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report any side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
5. How to store Zoledronic acid
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to the last day of that month.
The unopened vial does not require any special storage conditions.
The diluted Zoledronic acid solution should be used immediately in order to avoid microbial contamination.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
After dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 20° to 25°C and to 2° to 8°C. From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
6. Contents of the pack and other information
What Zoledronic acid contains
- The active substance is Zoledronic acid.
One ml concentrate contains 0.8 mg zoledronic acid corresponding to 0.8523 mg zoledronic acid monohydrate. One vial with 5 ml concentrate solution contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate.
- The other ingredients are: mannitol, sodium citrate, water for injections.
What Zoledronic acid looks like and contents of the pack
Zoledronic acid is supplied as a liquid, clear and colourless concentrate in a vial.
Each pack contains the vial with concentrate. Zoledronic acid is supplied in 5 ml clear glass vial with bromobutyl rubber stopper and aluminium cap with plastic flip-off seal.
Pack of 5 vials.
Marketing Authorisation Holder
Claris Lifesciences UK Limited Crewe Hall, Crewe, Cheshire, CW16UL,
United Kingdom.
Manufacturer
Peckforton Pharmaceuticals Limited Crewe Hall, Crewe, Cheshire, CW16UL,
United Kingdom
This Leaflet was last revised in 10/2016.
Other sources of Information
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu
O
LT\
o
LT\
o
o
o
o
-d-
Chemical and physical in-use stability has been -demonstrated for 24 hours at 20° to 25°C and to 2° to 8°C.
From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. The hydration status of patients must be assessed prior to and following administration of Zoledronic acid to ensure that they are adequately hydrated.
Since no data are available on the compatibility of Zoledronic acid with other intravenously administered substances, Zoledronic acid must not be mixed with other medications/substances and should always be given through a separate infusion line.
X